Heron Therapeutics Inc (HRTX) Shares Bought by Metropolitan Life Insurance Co. NY

Metropolitan Life Insurance Co. NY increased its position in Heron Therapeutics Inc (NASDAQ:HRTX) by 18.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 20,739 shares of the biotechnology company’s stock after purchasing an additional 3,177 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Heron Therapeutics were worth $806,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of HRTX. Wells Fargo & Company MN raised its holdings in shares of Heron Therapeutics by 86.6% in the 1st quarter. Wells Fargo & Company MN now owns 60,545 shares of the biotechnology company’s stock valued at $1,670,000 after purchasing an additional 28,095 shares during the period. Rhumbline Advisers raised its holdings in shares of Heron Therapeutics by 14.7% in the 1st quarter. Rhumbline Advisers now owns 49,228 shares of the biotechnology company’s stock valued at $1,359,000 after purchasing an additional 6,322 shares during the period. SG Americas Securities LLC bought a new stake in shares of Heron Therapeutics in the 1st quarter valued at about $183,000. State Board of Administration of Florida Retirement System raised its holdings in shares of Heron Therapeutics by 12.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 19,010 shares of the biotechnology company’s stock valued at $525,000 after purchasing an additional 2,131 shares during the period. Finally, Swiss National Bank raised its holdings in shares of Heron Therapeutics by 1.8% in the 1st quarter. Swiss National Bank now owns 100,300 shares of the biotechnology company’s stock valued at $2,768,000 after purchasing an additional 1,800 shares during the period.

In other Heron Therapeutics news, CFO Robert Hoffman sold 30,000 shares of the stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $38.17, for a total transaction of $1,145,100.00. Following the transaction, the chief financial officer now owns 1,280 shares in the company, valued at approximately $48,857.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Kevin C. Tang sold 2,695,000 shares of the stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $35.75, for a total transaction of $96,346,250.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,085,469 shares of company stock worth $111,612,708. Insiders own 16.20% of the company’s stock.

A number of equities research analysts have recently issued reports on HRTX shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $50.00 target price on shares of Heron Therapeutics in a report on Wednesday, August 8th. ValuEngine cut shares of Heron Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 2nd. Mizuho reaffirmed a “buy” rating and issued a $41.00 target price on shares of Heron Therapeutics in a report on Friday, June 22nd. Zacks Investment Research raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a report on Wednesday, July 18th. Finally, Cowen reissued a “buy” rating and issued a $54.00 price target on shares of Heron Therapeutics in a report on Thursday, June 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the company’s stock. Heron Therapeutics currently has an average rating of “Buy” and a consensus target price of $50.50.

Heron Therapeutics stock opened at $31.65 on Tuesday. Heron Therapeutics Inc has a twelve month low of $14.40 and a twelve month high of $42.90.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.14. The firm had revenue of $17.28 million for the quarter, compared to analysts’ expectations of $12.82 million. Heron Therapeutics had a negative net margin of 411.41% and a negative return on equity of 112.35%. The business’s revenue was up 103.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.80) EPS. research analysts expect that Heron Therapeutics Inc will post -2.2 EPS for the current year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading: What is a Tariff?

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply